 Mallinckrodt plc NYSE: MNK, a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration FDA has accepted for review the companys New Drug Application NDA for terlipressin, an investigational agent being evaluated for the treatment of hepatorenal syndrome type 1 HRS-1. On March 17, 2020 the company announced the completion of its rolling submission of the NDA for terlipressin. The FDA assigned a Prescription Drug User Fee Act PDUFA target date of September 12, 2020. 